Use of Ruxolitinib Cream Results in Economic Benefits Compared with Dupilumab in Treatment of Patients with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy

This model demonstrates that 1.5% ruxolitinib cream reduces treatment costs by over 80% compared to dupilumab in patients with moderate AD eligible for systemic therapy. Combined with comparable efficacy, these savings position ruxolitinib cream as a cost-effective treatment option.